Results 61 to 70 of about 2,272 (175)
BioMed Research International, Volume 2026, Issue 1, 2026.Acinetobacter baumannii is a globally prevalent Gram‐negative pathogen responsible for a substantial proportion of healthcare‐associated infections, particularly in intensive care units. Its ability to persist in hospital environments, form biofilms on medical devices, and evade host immune responses has contributed to the rapid emergence of multidrug ...
Krupa Bhaliya +7 more
wiley +1 more source
Viability of E. coli HM22 after treatment with rifamycin SV and eravacycline.
, 2021 (A) Effects of 100 μg/mL rifamycin SV on the viability of normal (black bars) and persister (patterned bars) cells of E. coli HM22. Means ± SE are shown (n = 3). (B) Intracellular concentration of rifamycin SV based on the reporter bioassay. Rifamycin SV
Karin Sauer (1993) +5 more
core +1 more source
BMC Infectious Diseases, 2019 Background In China multidrug-resistant bacteria pose a considerable threat to public health. Antimicrobial resistance has weakened the effectiveness of many medicines widely used today.
Chunjiang Zhao +6 more
doaj +1 more source
In Silico Pharmacokinetic Profile and Antimalarial Efficacy of 3‐Chloro‐4‐(4‐Chlorophenoxy)Aniline
Biochemistry Research International, Volume 2026, Issue 1, 2026.Despite the urgent need for new therapies to treat multidrug‐resistant virulent Plasmodium falciparum, many promising antimalarial candidates fail to progress to clinical use because their pharmacokinetic (PK) profile is poorly characterized. This study predicted the PK profile of a new compound, 3‐chloro‐4‐(4‐chlorophenoxy)aniline (ANI), in silico ...
Milka W. Waithera +5 more
wiley +1 more source
In vitro activity of eravacycline and mechanisms of resistance in enterococci
International Journal of Antimicrobial Agents, 2020 Eravacycline (ERC), the first fluorocycline, is a new tetracycline with superior activity to tigecycline (TGC) against many bacterial species. This work aimed to determine the in vitro activity of ERC compared with other tetracyclines against enterococcal clinical isolates and to analyse corresponding resistance mechanisms.
Boukthir, Sarrah +6 more
openaire +4 more sources
, 2022 In this study, we investigated the in vitro activity and resistance mechanisms of the new generation tetracycline agents, namely eravacycline, omadacycline, and tigecycline, against Staphylococcus aureus isolates. A total of 1,017 non-duplicate S. aureus
Yi Zhang (9093) +8 more
core +1 more source
Microbial Biotechnology, Volume 18, Issue 9, September 2025.Investigation of outer membrane vesicles from Acinetobacter baumannii for potential biotechnological applications. ABSTRACT Outer membrane vesicles (OMVs) are extracellular nanostructures released from Gram‐negative bacteria. Acinetobacter baumannii OMVs (AbOMVs) have been extensively studied and can thus be used as a model for understanding multiple ...
Beatriz Cano‐Castaño +5 more
wiley +1 more source
A review of antibiotic safety in pregnancy—2025 update
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 45, Issue 4, Page 227-237, April 2025.Abstract Antibiotics constitute the majority of prescriptions for women during pregnancy. Common bacterial infections, including urinary tract infections, skin and soft tissue infections, and upper and lower respiratory tract infections, are expected in pregnancy, similar to the general public.
Johny Nguyen +8 more
wiley +1 more source
Eravacycline for treatment of complicated intra-abdominal infections: the fire is not ignited! [PDF]
Annals of Translational Medicine, 2017 The worldwide surge of multi-drug resistant (MDR) Gram-negative infections has become a real threat in postsurgical and critically ill patients. Among the most dreaded MDR Gram-negatives are extended-spectrum β-lactamase (ESBL) and carbapenemase producing Enterobacteriaceae and MDR Pseudomonas species (1,2). Carbapenem-resistant Enterobacteriaceae (CRE)
Honoré, Patrick M, Spapen, Herbert D
openaire +3 more sources
Clinical Transplantation, Volume 39, Issue 4, April 2025.ABSTRACT Introduction Little is known about the epidemiology and management of gram‐negative bloodstream infections (GN‐BSIs) in patients after solid organ transplant (SOT). We describe epidemiology, treatment approaches, and outcomes in a subset of patients with SOT from a larger cohort with GN‐BSI. Methods This was a multicenter, retrospective cohort
Sarah B. Doernberg +11 more
wiley +1 more source